Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations

J Med Virol. 2008 Jun;80(6):937-41. doi: 10.1002/jmv.21138.

Abstract

An unexpected dramatic immune recovery was observed in a patient with full-blown AIDS receiving enfuvirtide-based antiretroviral therapy after multiple treatment failures. A complex interplay of viral and host factors, including the control of X4 viruses and proviral burden, may favor immune restoration with HIV neutralizing activity, despite persistent viremia.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Acquired Immunodeficiency Syndrome / immunology
  • Acquired Immunodeficiency Syndrome / virology
  • Adult
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes / cytology
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / immunology*
  • Drug Resistance, Viral / genetics
  • Enfuvirtide
  • Female
  • HIV Envelope Protein gp41 / pharmacology
  • HIV Envelope Protein gp41 / therapeutic use*
  • HIV Fusion Inhibitors / pharmacology
  • HIV Fusion Inhibitors / therapeutic use*
  • HIV-1* / drug effects
  • HIV-1* / genetics
  • Humans
  • Mutation
  • Neutralization Tests
  • Peptide Fragments / pharmacology
  • Peptide Fragments / therapeutic use*
  • Time Factors
  • Viremia / drug therapy*

Substances

  • HIV Envelope Protein gp41
  • HIV Fusion Inhibitors
  • Peptide Fragments
  • Enfuvirtide